Idorsia Ltd
SIX:IDIA

Watchlist Manager
Idorsia Ltd Logo
Idorsia Ltd
SIX:IDIA
Watchlist
Price: 0.6325 CHF -50.35% Market Closed
Market Cap: 114m CHF
Have any thoughts about
Idorsia Ltd?
Write Note

Idorsia Ltd
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Idorsia Ltd
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Idorsia Ltd
SIX:IDIA
Other Operating Expenses
CHf1.2m
CAGR 3-Years
960%
CAGR 5-Years
312%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Other Operating Expenses
-CHf3.3m
CAGR 3-Years
24%
CAGR 5-Years
11%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Other Operating Expenses
CHf233k
CAGR 3-Years
-9%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
No Stocks Found

Idorsia Ltd
Glance View

Market Cap
119.1m CHF
Industry
Biotechnology

Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

IDIA Intrinsic Value
Not Available

See Also

What is Idorsia Ltd's Other Operating Expenses?
Other Operating Expenses
1.2m CHF

Based on the financial report for Dec 31, 2023, Idorsia Ltd's Other Operating Expenses amounts to 1.2m CHF.

What is Idorsia Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
312%

The average annual Other Operating Expenses growth rates for Idorsia Ltd have been 960% over the past three years , 312% over the past five years .

Back to Top